ProgressImage ProgressImage
Anthem Biosciences Ltd
Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code 544449 border-img ISIN Demat INE0CZ201020 border-img Book Value 56.55 border-img NSE Symbol ANTHEM border-img Div & Yield % 0.22 border-img Market Cap ( Cr.) 50163.04 border-img P/E 78.13 border-img EPS 11.4 border-img Face Value 2
ParticularsMar 2026
()
Mar 2025
()
Mar 2024
()
Mar 2023
()
Mar 2022
()
Mar 2021
()
INCOME :       
Sales Turnover 2089.311840.651417.541056.921231.261103.24
Excise Duty 0.000.000.000.000.000.00
Net Sales 2089.311840.651417.541056.921231.261103.24
Other Income 182.08109.4470.52139.1748.9837.21
Stock Adjustments -98.6986.7141.239.011.37-39.12
Total Income 2172.702036.801529.291205.101281.611101.33
EXPENDITURE :       
Raw Materials 696.75828.08640.77348.29410.30407.88
Power & Fuel Cost 52.1342.5631.2938.9536.3234.23
Employee Cost 262.46251.76182.65153.24137.51142.19
Other Manufacturing Expenses 48.2946.2734.1321.1123.3822.76
Selling & Administrative Expenses 56.6056.4154.6760.6648.2133.66
Miscellaneous Expenses 47.1213.0810.2512.6811.4615.67
Less : Pre-operative Expenses Capitalised 0.000.000.000.000.000.00
Total Expenditure 1163.351238.15953.77634.92667.18656.38
Operating Profit 1009.35798.65575.52570.19614.44444.95
Interest 6.719.299.268.7110.0916.97
Gross Profit 1002.64789.36566.26561.48604.35427.98
Depreciation 99.5777.9481.4963.7057.7662.40
Profit Before Tax 903.07711.42484.77497.78546.59365.58
Tax 241.31182.03126.41120.05142.3996.70
Fringe Benefit tax 0.000.000.000.000.000.00
Deferred Tax -8.8023.21-16.42-7.94-1.79-2.43
Reported Net Profit 670.56506.19374.78385.67405.99271.31
Extraordinary Items -15.90-0.26-0.2140.84-0.14-0.14
Adjusted Net Profit 686.46506.45374.99344.83406.13271.45
Adjustment below Net Profit -67.06-50.62-71.60-139.350.000.00
P & L Balance brought forward 1979.721524.151220.97974.65568.66362.71
Statutory Appropriations 0.000.000.000.000.000.00
Appropriations 0.000.000.000.000.0026.08
P & L Balance carried down 2583.231979.721524.151220.97974.65607.93
Dividend 0.000.000.000.000.000.00
Preference Dividend 0.000.000.000.000.000.00
Equity Dividend % 100.000.000.000.000.000.00
Dividend Per Share(Rs) 2.000.000.000.000.000.00
Earnings Per Share-Unit Curr 11.949.056.706.76462.60319.76
Earnings Per Share(Adj)-Unit Curr 11.949.056.706.76462.60319.76
Book Value-Unit Curr 56.7044.2434.5830.531544.46826.76
Book Value(Adj)-Unit Curr 56.7044.2434.5830.531544.46826.76
`

ATTENTION INVESTORS : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day ...Issued in the interest of investors.   Prevent Unauthorized Transactions in your demat account Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day...... issued in the interest of investors.    KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.      No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment.No worries for refund as the money remains in investor's account.

Investor Protection and Arbitration Exchange Circulars and Rules - NSE BSE

Filing of complaints on SCORES – Easy & quick   |    Advisory for Investors   |    AP Details - NSE   |    AP Details - BSE   |    AP Details - MCX
KYC Process Flow   |    Investor Grievance Redressal Process Flow   |   Online Grievance Redressal   |    Voluntary Freezing/Blocking of Trading Account   |    Website Accessibility Statement   |    CDSL MyEasi   |    TRAI Notice on UCC   |    SEBI Risk Disclosure   |    Investor Notice

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing.

x
x
×
Let's Chat
imsl-img
close
refresh